Utilization of Chimeric Antigen Receptor (CAR) T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B cell non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Axicabtagene ciloleucel (YESCARTA ®, Kite Pharma, a Gilead Company) and tisagenlecleucel (KYMRIAH®, Novartis Pharmaceuticals Corp.) are two CD19-directed chimeric antigen receptor T cell (CD19 CAR T) products that are currently approved by the U.S. Food and Drug Administration, the European Medicines Agency, Health Canada, Ministr y of Health, Labor and Welfare (Japan) and Therapeutic Goods Administration (Australia) for treatment of specific subtypes of relapsed/ refractory aggressive B cell non-Hodgkin lymphoma (NHL).

Source: Biology of Blood and Marrow Transplantation - August 21, 2019 Category: Hematology Authors: Tania Jain, Merav Bar, Ankit J. Kansagra, Elise A. Chong, Shahrukh K. Hashmi, Sattva S. Neelapu, Michael Byrne, Elad Jacoby, Aleksandr Lazaryan, Caron A. Jacobson, Stephen M. Ansell, Farrukh T. Awan, Linda Burns, Veronica Bachanova, Catherine M. Bollard, Source Type: research